Vivace Therapeutics to Unveil First Clinical Data for a Cancer Drug Targeting the Hippo Pathway

Results from Phase 1 Trial of VT3989, a First-in-Class TEAD Autopalmitoylation Inhibitor, to be Reported in an Oral Presentation at AACR Annual Meeting 2023 SAN MATEO, Calif., March 15, 2023 /PRNewswire/ — Vivace Therapeutics, Inc., a small molecule discovery and development company…

Leave a Reply

Your email address will not be published. Required fields are marked *